Ostenil (Alendronate Sodium Trihydrate)

Alendronate sodium triacetate, the active ingredient in Ostenil, is a bisphosphonate presented as a oral tablet for systemic use. It is used to treat osteoporosis and other bone loss conditions in post‑menopausal women and men at risk of fracture.

GNH USA supplies Ostenil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Ostenil is a bisphosphonate that acts on the skeletal remodeling pathway to increase bone mineral density. - Osteoporosis: improves bone mineral density and reduces fracture risk in post‑menopausal women and men. - Paget’s disease of bone: helps normalize bone turnover and alleviate bone pain. - Glucocorticoid‑induced osteoporosis: mitigates bone loss associated with long‑term corticosteroid therapy.

Adverse reactions to alendronate are reported across a spectrum of frequency.

Common Side Effects: - Gastrointestinal irritation: dyspepsia, abdominal pain, or heartburn. - Musculoskeletal pain: bone, joint, or muscle aches. - Nausea or vomiting. - Constipation or diarrhea. - Headache.

Serious or Rare Side Effects: - Esophageal ulceration or perforation. - Atypical femoral fracture. - Osteonecrosis of the jaw. - Severe acute phase reaction with fever and musculoskeletal pain. - Hypocalcaemia. - Renal impairment in susceptible individuals.

When prescribing alendronate, clinicians should consider several safety aspects. - Assess renal function: dose adjustment may be needed in moderate renal impairment. - Ensure adequate calcium and vitamin D intake: supports bone health and reduces hypocalcaemia risk. - Instruct patient to remain upright for at least 30 minutes after dosing: minimizes esophageal irritation. - Review concomitant medications: avoid concurrent use with other oral bisphosphonates. - Monitor for signs of atypical fracture or jaw pain: discontinue if observed. - Store at ambient temperature: keep in the original packaging, protect from moisture.

Alendronate may interact with several medicines that affect absorption or bone metabolism.

Major Interactions (Avoid): - Antacids containing aluminium or magnesium: reduce alendronate absorption. - Calcium supplements taken concurrently: markedly decrease drug bioavailability. - Proton pump inhibitors (PPIs): may diminish absorption and increase gastrointestinal risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of upper gastrointestinal irritation. - Corticosteroids: additive effect on bone loss if not adequately protected. - Vitamin K antagonists (e.g., warfarin): may require INR monitoring due to potential interaction.